References

Arnt J, Hyttel J, Perregard J (1987) Dopamine D-1 receptor agonists combined with the selective D-2 agonist, quinpirole, facilitate the expression of oral stereotyped behavior in rats. Wur J Pharmacol 133:137-145.

Berger TW, Kaul S, Stricker EM, et al (1985) Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats. Brain Res 366:354-358.

Breese GR, Baumeister AA, Napier TC, et al (1985) Evidence that D1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine. J Pharmacol Exp Ther 235:287-295.

Breese GR, Duncan GE, Napier TC, et al (1987) 6-Hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1 and D2-dopamine agonists into the nucleus accumbens and striatum without changing dopamine antagonist binding. J Pharmacol Exp Ther 240:167-176.

Brown RW, Gass JT, Kostrzewa RM (2002) Ontogenetic quinpirole treatments produce spatial memory deficits and enhance skilled reaching in adult rats. Pharmacol Biochem Behav 72:591-600.

Brus R, Kostrzewa RM, Perry KW, et al (1994) Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment. J Pharmacol Exp Ther 268:231-237.

Brus R, Nowak P, Szkilnik R, et al (2004) Serotoninergics attenuate hyperlocomotor activity in rats. Potential new therapeutic strategy for hyperactivity. Neurotox Res 6, 317-325.

Casey DE (1987) Tardive dyskinesia. In: Meltzer HY, ed. Psychopharmacology. The Third Generation of Progress. New York: Raven, pp 1411-1419.

Chiu S, Paulose CS, Mishra RK (1981) Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-loeucyl-glycinamide. Science 214:1261-1262.

Criswell HE, Mueller RA, Breese GR (1989) Priming of D1-dopamine receptor responses: long-lasting behavioral supersensitivity to a D1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats. J Neurosci 9:125-133.

Egan MF, Hyde TM, Lleinman JE, et al (1995) Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose. Psychopharmacology 117:74-81.

Ellison GD, See RE (1989) Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia. Psychopharmacology (Berl) 98:564-566.

Gong L, Kostrzewa RM (1992) Supersensitized oral response to a serotonin agonist in neonatal 6-OHDA treated rats. Pharmacol Biochem Behav 41:621-623.

Gong L, Kostrzewa RM, Fuller RW, et al (1992) Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. J Pharmacol Exp Ther 261:1000-1007.

Gong L, Kostrzewa RM, Perry KW, et al (1993) Dose-related effects of a neonatal 6-OHDA lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Dev Brain Res 76:233-238.

Gong L, Kostrzewa RM, Li C (1994) Neonatal 6-OHDA and adult SKF 38393 treatments alter dopamine D1 receptor mRNA levels: absence of other neurochemical associations with the enhanced behavioral responses of lesioned rats. J Neurochem 63:1282-1290.

Gunne LM, Haggstron, JE (1983) Reduction in nigral glutamic acid decarbosylase in rats with neuroleptic-induced oral dyskinesia. Psychopharmacology (Berl) 81:191-194.

Gunne LM, Growdon J, Glaeser B (1982) Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology (Berl) 81:134-139.

Gunne LM, Bachus SE, Gale K (1988) Oral movements induced by interference with nigral GABA neurotransmission: relationship to tardive dyskinesias. Exp Neurol 100:459-469.

Huang N-Y, Kostrzewa RM (1994) Persistent oral dyskinesias in haloperidol-withdrawn neonatal 6-OHDA-lesioned rats. Eur J Pharmacol 271:433-437.

Huang N-Y, Kostrzewa RM, Li C, et al (1997) Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: absence of an association with the B for [3H]raclopride binding to neostriatal homogenates. J Pharmacol Exp Ther 280:26m8ax-276.

Jeste DV, Caligiuri MP (1993) Tardive dyskinesia. Schizophr Bull 19:303-315.

Kane JM, Woerner M, Weinhold P, et al (1982) A prospective study of tardive dyskinesia development: preliminary results. J Clin Psychopharmacol 2:345-349.

Klawans HL (1973) The pharmacology of tardive dyskinesia. Am J Psychiatry 130:82-86.

Knable MB, Hyde TM, Egan MF, et al (1994) Quantitative autoradiography of striatal dopamine D1, D2 and re-uptake sites in rats with vacuous chewing movements. Brain Res 646:217-222.

Koshikawa N, Aoki S, Tomiyama M, et al (1987) Sulpiride injection into the dorsal striatum increases methamphetamine-induced gnawing in rats. Eur J Pharmacol 133:119-125.

Kostrzewa RM (1995) Dopamine receptor supersensitivity. Neurosci Biobehav Rev 19:1-17.

Kostrzewa RM, Moratalla R (submitted) Serotonin and Parkinson disease.

Kostrzewa RM, Brus R (1991) Ontogenic homologous supersensitization of quinpirole-induced yawning in rats. Pharmacol Biochem Behav 39:517-519.

Kostrzewa RM, Gong L (1991) Supersensitized D1 receptors mediate enhanced oal activity after neonatal 6-OHDA. Pharmacol Biochem Behav 39:677-682.

Kostrzewa RM, Hamdi A, Kostrzewa FP (1990) Production of prolonged supersensitization of dopamine D2 receptors. Eur J Pharmacol 183:1411-1412.

Kostrzewa RM, Brus R, Kalbfleisch J (1991) Ontogenetic homologous sensitization to the antinociceptive action of quinpirole in rats. Eur J Pharmacol 209:157-161.

Kostrzewa RM, Gong L, Brus R (1992) Serotonin (5-HT) systems mediate dopamine (DA) receptor supersensitivity. Acta Neurobiol Exp 53:31-41.

Kostrzewa RM, Brus R, Rykaczewska M, et al (1993b) Low dose quinpirole ontogenically sensitizes to quinpirole-induced yawning in rats. Pharmacol Biochem Behav 44:487-489.

Kostrzewa RM, Brus R, Perry KW, et al (1993a) Age-dependence of a 6-hydroxydopamine lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Dev Brain Res 76:87-93.

Kostrzewa RM, Brus R, Kalbflesich JH, et al (1994) Proposed animal model of attention deficit hyperactivity disorder. Brain Res Bull 34:161-167.

Kostrzewa RM, Reader TA, Descarries L (1998) Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain. J Neurochem 70:889-898.

Kostrzewa RM, Brus R, Perry KW (1999) Interactive modulation by dopamine and serotonin neurons of receptor sensitivity of the alternate neurochemical system. Pol J Pharmacol 5:39-47.

Kostrzewa RM, Kostrzewa JP, Brus R (2003) Dopamine receptor supersensitivity: an outcome and index of neurotoxicity. Neurotox Res 5:111-118.

Kostrzewa RM, Kostrzewa JP, Nowak P, et al (2004) Dopamine D2 agonist priming in intact and dopamine-lesioned rats. Neurotox Res 6:457-462.

Kostrzewa RM, Huang N-Y, Kostrzewa JP, et al (2007) Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment. Neurotox Res 11:41-50.

Kostrzewa RM, Kostrzewa JP, Brown R, et al (2008a) Dopamine receptor supersensitivity: development, mechanisms, presentation, and clinical applicability. Neurotox Res 14:121-128.

Kostrzewa RM, Kostrzewa JP, Kostrzewa RA, et al (2008) Pharmacological models of ADHD. J Neural Transm 115, 287-298.

Levin ED, See RE, South D (1989) Effects of dopamine D1 and D2 receptor antagonists on oral activity in rats. Pharmacol Biochem Behav 34:43-48.

Lloyd KG, Willigens MT, Goldstein M (1985) Induction and reverse of dopamine dyskinesia in rat, cat, and monkey. Psychopharmacology (Berl) 85(suppl 2):200-210.

Mithani S, Atmadja S, Baimbridge KG, et al (1987) Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities. Psychopharmacology (Berl) 93:94-100.

Molloy AG, Waddington JL (1988) Behavioral responses to the selective D1-dopamine receptor agonist R-SK&F 38393 and the selective D2-agonist RU 24213 in young compared with aged rat. Br J Pharmacol 95:335-342.

Murray AM, Waddington JL (1989) The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1:D-2 interaction. Eur J Pharmacol 160:377-387.

Nowak P, Brus R, Kostrzewa RM (2001) Amphetamine-induced enhancement of neostriatal in vivo microdialysate dopamine content in rats, quinpirole-primed as neonates. Pol J Pharmacol 53:319-329.

Nowak P, Bortel A, D^browska J, et al (2007) Amphetamine and mCPP effects on dopamine and serotonin striatal in vivo microdialysates in an animal model of hyperactivity. Neurotox Res 11(2):131-144.

Plech A, Brus R, Kalbfleisch JH, et al (1995) Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats. Psychopharmacology 119:466-473.

Rosengarten H, Schweitzer JW, Friedhoff AJ (1983) Induction of oral dyskinesias in naive rats by D1 stimulation. Life Sci 33:2479-2482.

Rosengarten H, Schweitzer JW, Egawa J, et al (1983) Diminished D2 dopamine receptor function and the emergence of repetitive jaw movements. Adv Exp Med Biol 235:159-169.

Rosengarten H, Schweitzer JW, Egawa J, et al (1986) Diminished D2 dopamine receptor function and the emergence of repetitive jaw movements. Adv Exp Med Biol 235:159-167.

Rupniak NMJ, Jenner P, Marsden CD (1983) Cholinergic manipulation of perioral behavior-induced by chronic neuroleptic administration to rats. Psychopharmacology (Berl) 79:226-230.

Rupniak NMJ, Jenner P, Marsden CD (1985) Pharmacological characterization of spontaneous or drug-associated purposeless chewing movements in rats. Psychopharmacology (Berl) 85:71-79.

Salamone JD, Johnson CJ, McCullough LD, et al (1990) Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat. Psychopharmacology (Berl) 102:529-534.

Snyder AM, Zigmond MJ, Lund RD (1986) Sprouting of serotonergic afferents into striatum after dopamine depleting lesions in infant rats: a retrograde transport and immunocytochemical study. J Comp Neurol 245:274-281.

Tamminga CA, Crayton W, Chase TN (1979) Improvement in tardive dyskinesia after muscimol therapy. Arch Gen Psychiatry 36:595-598.

Waddington JL (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology (Berl) 101:431-447.

Waddington JL, Cross AJ, Gamble SJ, et al (1983) Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 220:530-532.

Understanding And Treating ADHD

Understanding And Treating ADHD

Attention Deficit Disorder or ADD is a very complicated, and time and again misinterpreted, disorder. Its beginning is physiological, but it can have a multitude of consequences that come alongside with it. That apart, what is the differentiation between ADHD and ADD ADHD is the abbreviated form of Attention Deficit Hyperactive Disorder, its major indications being noticeable hyperactivity and impulsivity.

Get My Free Ebook


Post a comment